Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Scandasia.com14h
Novo Nordisk sues Singapore biotech firm over $1.3 billion acquisition dispute
Novo Nordisk, the Danish pharmaceutical giant, has filed a lawsuit against Singapore-based KBP Biosciences and its founder, ...
Hosted on MSN13d
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a ...
Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
2 Important Insights From Novo Nordisk's Earnings Call
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Yahoo Finance26d
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...